View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 2, 2019updated 12 Jul 2022 11:59am

Suven fails to meet target in trial of Alzheimer’s drug masupirdine

Indian pharmaceutical company Suven Life Sciences has failed to meet the primary endpoint in its Phase IIA proof-of-concept study that evaluated the efficacy, safety and tolerability of masupirdine (SUVN-502) for the treatment moderate Alzheimer’s disease.

Indian pharmaceutical company Suven Life Sciences has failed to meet the primary endpoint in its Phase IIA proof-of-concept study that evaluated the efficacy, safety and tolerability of masupirdine (SUVN-502) for the treatment moderate Alzheimer’s disease.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The trial was conducted at centres across the US and focused on advanced-stage Alzheimer’s patients (moderate Alzheimer’s) treated with standard of care donepezil and memantine.

The triple-therapy consists of masupirdine, donepezil and memantine and is based on pre-clinical cognition models where masupirdine enhanced the effects of combined treatment with donepezil and memantine.

Masupirdine is a selective serotonin 6 receptor antagonist being developed for the symptomatic treatment of Alzheimer’s dementia.

The primary efficacy endpoint of the study was meaningful improvements from baseline to week 26 in ADAS-Cog 11 score. Secondary outcome measures were MMSE, ADCS-ADL, CDR-SB, NPI, C-SDD, safety and tolerability assessment.

The study found that masupirdine is safe and well-tolerated without significant adverse events. However, the company said that the triple therapy failed to meet its primary endpoint.

Suven Life Sciences said that the sub-population of patients treated with masupirdine showed a significant improvement and reduction in the behavioural symptoms in agitation/aggression and delusions/hallucination as assessed by the NPI subscale scores.

The Phase IIA randomised, double-blind, placebo-controlled, multi-centre, parallel-group study was conducted to compare the efficacy and safety of two doses of masupirdine (50mg and 100mg per day) to placebo in moderate Alzheimer’s patients.

The study involved 564 subjects who had Alzheimer’s for at least one year and scored between 12 and 20 in mini-mental state examination (MMSE).

Patients were being treated with stable doses of either donepezil 10mg/day and memantine 10mg twice a day, namenda XR (memantine) 28mg/day, or namzaric (28mg memantine HCl extended-release/10mg donepezil HCl) once a day for at least three months.

The 30-week study included a 26-week double-blind treatment period followed by a four-week single-blind placebo washout period.

The safety of masupirdine was evaluated through physical and neurological examinations, blood pressure, ECGs, laboratory tests, and a review of adverse events.

Suven Life Sciences said that masupirdine appeared to be well-tolerated in the Alzheimer’s population, with most reported adverse events similar to placebo. There were no significant changes in physical, neurological, cardiology and laboratory tests.

Patients who completed the study were allowed to participate in a compassionate Expanded Access Program (EAP) with masupirdine (50mg daily) for an additional six to 12 months.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena